Rio Tinto on Track for Largest Percent Increase Since September 2023 — Data Talk
Rio Tinto plc Sponsored ADR (RIO) is currently at $65.54, up $2.54 or 4.02%
--Would be highest close since Feb. 23, 2024, when it closed at $65.98
--On pace for largest percent increase since Sept. 14, 2023, when it rose 4.63%
--Snaps a three day losing streak
--Up 2.82% month-to-date
--Down 11.99% year-to-date
--Down 52.76% from its all-time closing high of $138.73 on May 16, 2008
--Down 2.46% from 52 weeks ago (April 10, 2023), when it closed at $67.19
--Down 12.35% from its 52-week closing high of $74.77 on Dec. 27, 2023
--Up 12.29% from its 52-week closing low of $58.36 on Aug. 16, 2023
--Traded as high as $65.80; highest intraday level since Feb. 23, 2024, when it hit $66.49
--Up 4.44% at today's intraday high; largest intraday percent increase since Sept. 14, 2023, when it rose as much as 4.74%
All data as of 10:42:08 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 08, 2024 10:59 ET (14:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track